The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease - Wikidata - wikimedia - TriplyDB

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

http://www.wikidata.org/entity/Q26858893

about

The evolving role of response-adapted PET imaging in Hodgkin lymphoma Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.Primary intratesticular rhabdomyosarcoma: A case report and literature review Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET).Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine Oncologists’ Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the Turkish Oncology Group (TOG)Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas.Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma.Application value of diffusion weighted whole body imaging with background body signal suppression in monitoring the response to treatment of bone marrow involvement in lymphoma.The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.

P2860

Q26750993-0B59A3F6-6D37-46F2-8636-337A7D9742C7 Q38418605-5330605A-17CC-4108-911F-9CD225CD7571 Q38549745-9D408939-B248-4B42-ACDB-5D17ED6C67D7 Q38740422-F9E45881-3FEB-4118-B66A-9EF476849A4C Q39720437-DC3691BD-E5AF-4FA7-B5C4-3C2AF6DB479A Q42287385-E6AC83A5-D2B3-456B-80A7-0CF1B3E61025 Q42361969-D9EB5301-D28A-4904-BD38-0B72C54E559B Q47207408-014187B2-04FD-46DA-8D08-D3D0773CF04F Q52715715-53EAB306-D4C1-418E-8857-DA204779CC34 Q52868414-59AA3947-36E2-4C9A-9A22-8CBD69CAFBF3 Q52952250-22E8955F-B4D0-43A7-B218-CA051B891926 Q52983083-FD9420E1-E0BD-4ED6-A73C-B9B1ABCE6519 Q53011053-4653CE48-BEF3-4365-A803-6447EA3E9B0F

P2860

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

http://www.wikidata.org/entity/Q26858893

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@ast

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@en

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@nl

type

label

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@ast

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@en

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@nl

prefLabel

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@ast

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@en

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@nl

P1433

Q26858893-072FD27B-A04E-46FF-9121-1A488928FA1A

P1476

Q26858893-C1EFD1ED-0371-4221-8F51-E69040366976

P2093

Q26858893-6DD8191C-1F4C-445F-8ADD-CCB005E9E7F1

P2860

Q26858893-0083F8AC-10BB-4C1D-97C6-1451EE047B9B

Q26858893-013E1EA5-37DA-4F56-9137-5E5153D37A94

Q26858893-028195C7-E603-43A5-BA4E-3B91E84D1CED

Q26858893-05FD7B01-7A8D-4741-AE38-E1C665D5FD12

Q26858893-0BBA9016-1323-4888-AE72-9D073D9CA373

Q26858893-1DF707D2-B6CC-451C-BD98-75EA1ADF258E

Q26858893-21DF84F0-25B5-4C31-9B91-3FA550502160

Q26858893-22AA74B3-727F-4F75-8685-715197EDFAE9

Q26858893-25CA2F5C-3298-4DF9-B446-B02C68750148

Q26858893-30535F67-2862-4847-A081-C60ECEEA708F

P304

Q26858893-98052A8B-9F1F-4086-A19E-0F63879E72DB

P31

Q26858893-D2E230B4-3EE2-472E-95DB-698529D76E2F

P356

Q26858893-640E3ECF-EA09-4990-A5AD-7171B298173E

P407

Q26858893-DC7A4ECC-3647-4A85-B927-A2F7C4A08F9C

P433

Q26858893-C06A80CD-F19C-46A4-A80B-A4C04842A0FF

P478

Q26858893-217E0448-01BD-489A-8671-C0550563878C

P50

Q26858893-075DD557-7704-4CFF-BCC1-38940666407D

P577

Q26858893-BBEA86AF-F7B4-400D-971A-6060927A3DB8

P698

Q26858893-CEADD6ED-B2B5-49CE-842D-47CE6A955977

P932

Q26858893-2B3E213D-7139-49A9-9AF5-5D3D3C2DD3E7

P356

BLOOD-2014-05-577627

P1433

P1476

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

@en

P2093

Lale Kostakoglu

http://www.w3.org/2001/XMLSchema#string

P2860

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.

Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.

Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks

Treatment of Hodgkin lymphoma: a 50-year perspective.

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

P304

3356-3364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-05-577627

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25428223

http://www.w3.org/2001/XMLSchema#string

P932

4467863

http://www.w3.org/2001/XMLSchema#string